Molecular insights provide the critical path to disease mitigation

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 1, 2014, Pages 3-7

  Waldman, S A ^a   Terzic, A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BOCEPREVIR; CRIZOTINIB; DACARBAZINE; FINGOLIMOD; INTERLEUKIN 2; NATALIZUMAB; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA; RAF PROTEIN; RIBAVIRIN; TELAPREVIR; VEMURAFENIB;

ALZHEIMER DISEASE; ANTIBIOTIC RESISTANCE; ANTIVIRAL THERAPY; APOPTOSIS; ATTITUDE TO ILLNESS; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL INTERACTION; CELL MIGRATION; CHRONIC DISEASE; CLINICAL PATHWAY; CLINICAL PRACTICE; DEATH; DEMENTIA; DEPRESSION; DISEASE CONTROL; HEALTH CARE DELIVERY; HEPATITIS C; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULAR EPIDEMIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE SCLEROSIS; OBESITY; PATHOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN PROCESSING; PUBLIC HEALTH PROBLEM; REVIEW;

EID: 84890962687     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.211     Document Type: Review

References (24)

1. Waldman, S.A. & Terzic, A. Information hierarchies optimize patient-centered solutions. Clin. Pharmacol. Ther. 93, 3-7 (2013).
2. Arrell, D.K. & Terzic, A. Interpreting networks in systems biology. Clin. Pharmacol. Ther. 93, 389-392 (2013).
3. Harrold, J.M., Ramanathan, M. & Mager, D.E. Networkbased approaches in drug discovery and early development. Clin. Pharmacol. Ther. 94, 651-658 (2013).
4. Waldman, S.A. & Terzic, A. Systems-based discovery advances drug development. Clin. Pharmacol. Ther. 93, 285-287 (2013).
5. Gonzalez de Castro, D., Clarke, P.A., Al-Lazikani, B. & Workman, P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin. Pharmacol. Ther. 93, 252-259 (2013).
6. Jacunski, A. & Tatonetti, N.P. Connecting the dots: applications of network medicine in pharmacology and disease. Clin. Pharmacol. Ther. 94, 659-669 (2013).
7. Lewis, J.P., Yerges-Armstrong, L.M., Ellero-Simatos, S., Georgiades, A., Kaddurah-Daouk, R. & Hankemeier, T. Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clin. Pharmacol. Ther. 94, 570-573 (2013).
8. Roden, D.M. & Tyndale, R.F. Genomic medicine, precision medicine, personalized medicine: what's in a name? Clin. Pharmacol. Ther. 94, 169-172 (2013).
9. Reynolds, K.S. Acceleration of drug development: a collaboration of many stakeholders. Clin. Pharmacol. Ther. 93, 455-459 (2013).
10. Evans, W.E., Crews, K.R. & Pui, C.H. A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin. Pharmacol. Ther. 94, 224-229 (2013).
11. Jang, S. & Atkins, M.B. Treatment of BRAF mutant melanoma: the role of vemurafenib and other therapies. Clin. Pharmacol. Ther. 95, 24-31 (2014).
12. Hansen, J. & Iyengar, R. Computation as the mechanistic bridge between precision medicine and systems therapeutics. Clin. Pharmacol. Ther. 93, 117-128 (2013).
13. Au, J.S. & Pockros, P.J. Novel therapeutic approaches for hepatitis C. Clin. Pharmacol. Ther. 95, 78-88 (2014).
14. Muir, A.J. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens Clin. Pharmacol. Ther.; e-pub ahead of print 4 October 2013.
15. Kantarci, O.H., Pirko, I. & Rodriguez, M. Novel immunomodulatory approaches for the management of multiple sclerosis. Clin. Pharmacol. Ther. 95, 32-44 (2014).
16. Solomon, B., Wilner, K.D. & Shaw, A.T. Current status of targeted therapy for anaplastic lymphoma kinase- rearranged non-small cell lung cancer. Clin. Pharmacol. Ther. 95, 15-23 (2014).
17. Kesselheim, A.S., Wang, B. & Avorn, J. Defining " innovativeness" in drug development: a systematic review. Clin. Pharmacol. Ther. 94, 336-348 (2013).
18. Waldman, S.A. & Terzic, A. The value proposition of molecular medicine. Clin. Transl. Sci. 5, 108-110 (2012).
19. Waldman, S.A. & Terzic, A. Translational medicine individualizes healthcare discovery, development and delivery. Foreword. Biomark. Med. 7, 1-3 (2013).
20. Milne, C.-P. Prospects for rapid advances in the development of new medicines for special medical needs. Clin. Pharmacol. Ther. 95, 98-109 (2014).
21. Cummings, J. & Zhong, K. Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations. Clin. Pharmacol. Ther. 95, 67-77 (2014).
22. Ogishima, S. et al. A map of Alzheimer's disease-signaling pathways: a hope for drug target discovery. Clin. Pharmacol. Ther. 93, 399-401 (2013).
23. Kim, G.W., Lin, J.E., Blomain, E.S. & Waldman, S.A. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin. Pharmacol. Ther. 95, 53-66 (2014).
24. Waldman, S.A. & Terzic, A. Knowledge cycle transforms therapeutic innovation. Clin. Pharmacol. Ther. 91, 3-8 (2012).